Corbus Pharmaceuticals Holdings, Inc.
CRBP · XNASCIK 1595097fmd_0539BCYS9397MCFKQCV3VGTNGEManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2013 to Sep 30, 2026, 53 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 2 | 2 | 5 | 36 | 4 | 1 | 0 | – | – | – |
| Net interest income | – | – | – | 1 | (1) | (2) | (2) | (3) | – | – |
| Net investment income | – | – | – | – | – | – | – | 2 | 6 | 6 |
| Research and development | 15 | 26 | 49 | 90 | 98 | 36 | 16 | 31 | 32 | 70 |
| Total operating expenses | 22 | 35 | 62 | 113 | 127 | 57 | 40 | 45 | 49 | 85 |
| Operating income | (20) | (33) | (57) | (77) | (123) | (56) | (40) | (45) | (49) | (85) |
| Interest expense | 0 | 0 | – | 0 | 1 | 3 | 3 | 4 | 2 | 0 |
| Interest and investment income | – | – | 1 | 1 | – | – | – | – | – | – |
| Other non-operating income (expense) | (0) | 0 | 1 | 6 | 12 | 10 | (3) | 0 | 9 | 7 |
| Income tax expense | – | – | – | – | – | – | – | – | 0 | 0 |
| Net income | (20) | (32) | (56) | (71) | (111) | (46) | (42) | (45) | (40) | (79) |
| Net income to common shareholders | – | – | – | – | – | – | – | – | – | – |